Review



sepantronium bromide  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    TargetMol sepantronium bromide
    Sepantronium Bromide, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/YM155/pm41308634-49-10-41
    Average 93 stars, based on 7 article reviews
    sepantronium bromide - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
    Article Snippet: Drugs including ML-323 (Cat# T1757), Adavosertib (Cat# T2077), Sepantronium bromide (Cat# T2111), Ceralasertib (Cat# T3338), Paclitaxel (Cat# T0968), and Brilanestrant (Cat# T5118) were purchased from Topscience (Shanghai, China).

    Article Title: Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma.
    Article Snippet: Drugs including ML-323 (Cat# T1757), Adavosertib (Cat# T2077), Sepantronium bromide (Cat# T2111), Ceralasertib (Cat# T3338), Paclitaxel (Cat# T0968), and Brilanestrant (Cat# T5118) were purchased from Topscience (Shanghai, China).

    Article Title: Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single-Cell Resolution.
    Article Snippet: Cladribine (T2558), homoharringtonine (T3380), azacitidine (T1339), cytarabine (T1272), venetoclax (T2119), sepantronium bromide (T2111), selinexor (T6106), ruxolitinib (T1829), panobinostat (T2383), idarubicin hydrochloride (T6010), daunorubicin (T1511L), ferrostatin- 1 (T6500), necrostatin- 1 (T1847), Z- VAD(OH)- FMK (T7020), and T- 5224 (T5416) were purchased from TargetMol (Boston, United States).



    Similar Products

    sepantronium bromide ym 155  (MedChemExpress)
    94
    MedChemExpress sepantronium bromide ym 155
    Sepantronium Bromide Ym 155, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/Sepantronium/pm41534785-86-19-23
    Average 94 stars, based on 1 article reviews
    sepantronium bromide ym 155 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sepantronium bromide  (TargetMol)
    93
    TargetMol sepantronium bromide
    Sepantronium Bromide, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/YM155/pm41308634-49-10-41
    Average 93 stars, based on 1 article reviews
    sepantronium bromide - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    sepantronium bromide ym155  (Ambeed Inc)
    86
    Ambeed Inc sepantronium bromide ym155
    Sepantronium Bromide Ym155, supplied by Ambeed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/bromide+sepantronium+ym155/pm40714660-40-0-6
    Average 86 stars, based on 1 article reviews
    sepantronium bromide ym155 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ym155  (MedChemExpress)
    94
    MedChemExpress ym155
    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with <t>YM155</t> for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
    Ym155, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/Sepantronium+bromide/pmc12202856-28-5-10
    Average 94 stars, based on 1 article reviews
    ym155 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sepantronium bromide ym155  (Selleck Chemicals)
    94
    Selleck Chemicals sepantronium bromide ym155
    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with <t>YM155</t> for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
    Sepantronium Bromide Ym155, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/YM155/bio_rxiv__2025__04__25__650475-353-105-108
    Average 94 stars, based on 1 article reviews
    sepantronium bromide ym155 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sepantronium bromide  (GraphPad Software Inc)
    90
    GraphPad Software Inc sepantronium bromide
    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with <t>YM155</t> for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
    Sepantronium Bromide, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/sepantronium+bromide/pmc11822212__41467_2025_56504_MOESM1_ESM-98-6-10
    Average 90 stars, based on 1 article reviews
    sepantronium bromide - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sepantronium bromide  (MedChemExpress)
    94
    MedChemExpress sepantronium bromide
    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with <t>YM155</t> for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
    Sepantronium Bromide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/Sepantronium/pm39903759-357-24-26
    Average 94 stars, based on 1 article reviews
    sepantronium bromide - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sepantronium bromide treatment  (MedChemExpress)
    94
    MedChemExpress sepantronium bromide treatment
    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with <t>YM155</t> for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
    Sepantronium Bromide Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sepantronium+bromide/Sepantronium/pmc11948012-241-3-16
    Average 94 stars, based on 1 article reviews
    sepantronium bromide treatment - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with YM155 for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.

    Journal: Cancer Research Communications

    Article Title: Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells

    doi: 10.1158/2767-9764.CRC-25-0058

    Figure Lengend Snippet: HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with YM155 for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.

    Article Snippet: Panobinostat (HY-10224), romidepsin (HY-15149), and YM155 (HY-101-94) were obtained from MedChemExpress.

    Techniques: Western Blot, RNA Sequencing, Expressing, CRISPR, Alamar Blue Assay